Drug
Octreotide Depot Formulation CAM2029 clinical trials
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
Camurus AB (5)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Octreotide Depot Formulation CAM2029 is read from its arms, and is right about nine times in ten.
Testing it · 5
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With AcromegalyCompletedPhase 3Camurus ABNCT04076462Written as CAM2029 (octreotide subcutaneous depot)
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NETActive, not recruitingPhase 3Camurus ABNCT05050942Written as CAM2029
- A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLDActive, not recruitingPhase 2/3Camurus ABNCT05281328Written as CAM2029
- A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With AcromegalyCompletedPhase 3Camurus ABNCT04125836Written as CAM2029 (octreotide subcutaneous depot)
- Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)CompletedPhase 2Camurus ABNCT02299089Written as octreotide FluidCrystal® injection depot